Key facts
- It has raised $14.6M; the latest was Early Stage VC in May 2025.
- Notable investors include CAS Star, Cowin Capital, China National Nuclear, Guohong Zhizhen, Sunland Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Hexin (Suzhou)
- ·The full record, as it builds
Funding rounds
No funding rounds for Hexin (Suzhou) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hexin (Suzhou)
Developer of nuclide drugs designed to integrate targeted diagnosis and treatment. The company's drugs utilize the core technology of positron emission tomography (PET) contrast agents and targeted radiotherapy, enabling healthcare providers to diagnose and treat pancreatic cancers more effectively.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- hexin-med.com/
- Ownership
- Privately Held (backing)
Hexin (Suzhou) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hexin (Suzhou) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hexin (Suzhou) in its N-PORT filings yet. We sweep new filings monthly.